Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | Unmet needs in ET and future considerations

Aaron Gerds • 24 Aug 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Rare Diseases Interferon

Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, briefly discusses unmet needs in essential thrombocythemia (ET), highlighting the importance of identifying patient risk for thrombotic events, and improving therapeutic options for patients. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Consulting/Advisory for CTI Biopharma, GSK/Sierra Oncology, Morphosys, ParmaEssentia, Imago, AbbVie

More from Aaron Gerds

1:27
Real-world use of fedratinib in patients with MF who have failed on ruxolitinib
Aaron Gerds • 6 Dec 2023
1:56
Treating elderly, non-transplant eligible patients with MF
Aaron Gerds • 6 Dec 2023
2:39
The MOST study: differences in disease progression amongst patients with low-risk MF
Aaron Gerds • 6 Dec 2023
1:30
XPORT-MF-044 trial: evaluating selinexor in JAK inhibitor-naïve MF and moderate thrombocytopenia
Aaron Gerds • 6 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals